Andlauer Healthcare Group (AND) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was $159.6M, up 1.8% year-over-year, with strong Canadian logistics and distribution growth offset by U.S. truckload weakness.

• Net income for Q3 2024 was $16.3M (CAD 0.41 per diluted share), up from $15.3M last year.

• EBITDA margin reached a record 25.9% for the quarter, up from 24.9% a year ago.

• Cash flow from operations for the nine months was $101.8M, with cash and equivalents at $36M as of September 30, 2024.

• Share repurchases and dividends led to a reduction in equity and cash balances.

Financial highlights

• Operating income for Q3 2024 was $23.8M, up 9.6% year-over-year.

• Healthcare logistics segment revenue was CAD 44.1M, up 4.7% year-over-year.

• Specialized transportation segment revenue was CAD 115.5M, up 0.8% year-over-year.

• EBITDA totaled CAD 41.3M, up 5.9% year-over-year.

• Dividends paid in the nine months totaled $12.4M ($0.31/share), up from $10.5M in the prior year.

Outlook and guidance

• Canadian business expected to maintain robust, high single-digit growth into 2025, focusing on network expansion and efficiency.

• U.S. business has likely reached its trough; stabilization and potential growth expected in 2025 due to easier comps and focus on higher-value segments.

• Q4 expected to see a modest seasonal bump, less pronounced than last year due to a large client onboarding in Q4 2023.

• Management targets a net leverage ratio below 3.0, with the current ratio at 0.74.

• Ongoing capital investments in logistics and transportation equipment are expected to support future growth.